Health insurer Excellus will not fund Alzheimer’s drug Aduhelm
pharmaphorum
AUGUST 12, 2021
The company – said to be the largest health insurer in New York – said in a statement that Aduhelm (aducanumab) remains an investigational drug, even though it was approved by the FDA in June for Alzheimer’s, according to a media report.
Let's personalize your content